AU664189B2 - Modulation of cellular response to external stimuli - Google Patents

Modulation of cellular response to external stimuli Download PDF

Info

Publication number
AU664189B2
AU664189B2 AU22475/92A AU2247592A AU664189B2 AU 664189 B2 AU664189 B2 AU 664189B2 AU 22475/92 A AU22475/92 A AU 22475/92A AU 2247592 A AU2247592 A AU 2247592A AU 664189 B2 AU664189 B2 AU 664189B2
Authority
AU
Australia
Prior art keywords
cells
cell
agent
amount
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22475/92A
Other languages
English (en)
Other versions
AU2247592A (en
Inventor
James A. Bianco
Stuart L Bursten
Jack W. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2247592A publication Critical patent/AU2247592A/en
Application granted granted Critical
Publication of AU664189B2 publication Critical patent/AU664189B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU22475/92A 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli Ceased AU664189B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70499291A 1991-05-24 1991-05-24
US704992 1991-05-24
US73222791A 1991-07-16 1991-07-16
US732227 1991-07-16
PCT/US1992/004349 WO1992021344A2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
AU2247592A AU2247592A (en) 1993-01-08
AU664189B2 true AU664189B2 (en) 1995-11-09

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22475/92A Ceased AU664189B2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP0573617A1 (cg-RX-API-DMAC7.html)
JP (1) JP3566719B2 (cg-RX-API-DMAC7.html)
AU (1) AU664189B2 (cg-RX-API-DMAC7.html)
CA (1) CA2109796C (cg-RX-API-DMAC7.html)
IE (1) IE921683A1 (cg-RX-API-DMAC7.html)
IL (1) IL101982A (cg-RX-API-DMAC7.html)
WO (1) WO1992021344A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
DK0584347T3 (da) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995024199A2 (en) * 1994-03-08 1995-09-14 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
EP0801568B1 (en) * 1994-12-29 2002-07-17 The Regents of the University of California Compounds for inhibition of ceramide-mediated signal transduction
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
EP1091960A1 (en) * 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
KR20090084149A (ko) * 2008-01-31 2009-08-05 한국과학기술연구원 뇌암 예방 또는 치료용 조성물
US20110039869A1 (en) * 2008-01-31 2011-02-17 Korea Institute Of Science And Technology Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
WO1989005145A1 (en) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Method of inhibiting the activity of leukocyte derived cytokines
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
IL100536A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine Stopping an immune response and relieving adverse conditions resulting from intracellular intervention in an immune response
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
DK0514789T3 (cg-RX-API-DMAC7.html) * 1991-05-23 1997-02-17 Hoechst Ag

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
WO1989005145A1 (en) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Method of inhibiting the activity of leukocyte derived cytokines
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions

Also Published As

Publication number Publication date
IL101982A0 (en) 1992-12-30
EP0573617A1 (en) 1993-12-15
IL101982A (en) 2000-02-29
CA2109796C (en) 2004-04-27
JPH07500085A (ja) 1995-01-05
JP3566719B2 (ja) 2004-09-15
WO1992021344A3 (en) 1993-12-09
AU2247592A (en) 1993-01-08
IE921683A1 (en) 1992-12-02
EP1214938A3 (en) 2003-08-06
WO1992021344A2 (en) 1992-12-10
EP0573617A4 (cg-RX-API-DMAC7.html) 1994-02-09
CA2109796A1 (en) 1992-12-10
EP1214938A2 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
US5856115A (en) Assay for identification therapeutic agents
AU664189B2 (en) Modulation of cellular response to external stimuli
EP1778224B1 (en) Flt3 inhibitors for immune suppression
JP2753395B2 (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
JP3140021B2 (ja) Ｔｎｆ阻害剤含有医薬組成物
US5440041A (en) Acetal or ketal substituted xanthine compounds
JP3723206B2 (ja) ムラミルペプチドとサイトカインとを組み合わせることを特徴とするヒトに用いる治療用組成物
EP1694331A1 (en) Methods for suppressing an immune response or a treating a proliferative disorder
JP2845622B2 (ja) インターロイキン―２とヒスタミン、その類似体又はｈ▲下２▼―受容体アゴニストを含む抗腫瘍性製剤
EP1401415B1 (en) Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
CA3023974A1 (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
EP0311616B1 (en) Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
JP2018009011A (ja) ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
Thompson et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma
CN100572530C (zh) 使用L-α-溶血磷脂酰胆碱获得单核细胞体外分化成成熟树突细胞
US20220079915A1 (en) Immunosuppressive pharmaceutical composition and application thereof
EP0692251A1 (en) Use of methotrexate for the manufacture of a medicament for the treatment of lung capillary leak
Chao et al. Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation
Strom et al. Regulation of alloimmunity by cyclic nucleotides
Petros et al. The Pharmacologic Effects of Recombinant, Human Colony‐Stimulating Factors and Their Modulation by Theophylline
CA2105378A1 (en) Compositions and methods of treatment of a variety of disorders utilizing etianate and agonists thereof
Moore et al. Acute Graft-Versus-Host Disease
Flierl et al. Upregulation of Phagocyte-Derived Catecholamines Augments the Acute Inflammatory